Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd.
Plaintiff: Regeneron Pharmaceuticals, Inc.
Defendant: Samsung Bioepis Co., Ltd.
Case Number: WVN/1:23-CV-00106
Filed: December 27, 2023
Court: Judicial Panel on Multidistrict Litigation
Presiding Judge: Thomas S Kleeh
Nature of Suit: Other
RSS RSS Track this Docket
Docket Report

This docket was last retrieved on February 16, 2024. A more recent docket listing may be available from PACER.

Date Filed Document Text
February 16, 2024 Opinion or Order Filing 15 HEARING ORDER re: pldg. ( #1 in MDL No. 3103) - SECTION A (DESIGNATED FOR ORAL ARGUMENT) PANEL HEARING set for 3/28/2024 in Charleston, Sout h Carolina. Notices of Presentation or Waiver of Oral Argument due on or before 3/4/2024.#Notice of Presentation or Waiver of Oral Argument form (JPML form 9) can be downloaded from our website.Signed by Judge Karen K. Caldwell, Chair, PANEL ON MULTIDISTRICT LITIGATION, on 2/16/2024. (Attachments: #1 Courthouse Advisory) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (RH)
February 12, 2024 Filing 14 MINUTE ORDER CLOSING BRIEFING re: pldg. ( #1 in MDL No. 3103), ( #2 in MDL No. 3103) Briefing in this matter is now closed. The parties to actions on the motion(s) remain under a duty, pursuant to Panel Rules 6.1(f) and 6.2(d), to notify the Clerk of the Panel promptly of potential tag-along actions, as well as any development that moots the motion or fully disposes of any action on the motion. Parties in any potential tag-along action may file an Interested Party response, but must do so promptly, and in any event, no later than the Thursday prior to the hearing session at which the motion for transfer is to be heard by the Panel.Signed by Clerk of the Panel Tiffaney D. Pete on 2/12/2024. Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (LH)
February 12, 2024 Filing 13 ERRATA - to (10 in CAC/2:24-cv-00264, #24 in MDL No. 3103, 11 in WVN/1:22-cv-00061, 12 in WVN/1:23-cv-00089, 10 in WVN/1:23-cv-00094, 10 in WVN/1:23-cv-00097, 10 in WVN/1:23-cv-00106) - Filed by Defendants Formycon AG, #et al.Samsung Bioepis, CO., LTD.,, Celltrion, Inc., Samsung Bioepis Co., Ltd. #[Suppress List] (Attachments: #1 Corrected Response in Opposition (Joint), #2 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Traupman, Matthew)
February 9, 2024 Filing 12 REPLY TO RESPONSE TO MOTION FOR TRANSFER re: pldg. ( #1 in MDL No. 3103), ( 24 , 26 , 27 in MDL No. 3103) Filed by Plaintiff Regeneron Pharmaceuticals, Inc. (Attachments: #1 Exhibit 8, #2 Exhibit 9, #3 Exhibit 10, #4 Exhibit 11, #5 Exhibit 12, #6 Exhibit 13, #7 Exhibit 14, #8 Exhibit 15, #9 Schedule of Actions, #10 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Berl, David) Modified on 2/12/2024 (LH). ADDED MDL LINKS, REMOVED DUPLCIATE PARTIES AND DUPLICATE ATTACHMENT NAMES
February 2, 2024 Filing 11 RESPONSE IN OPPOSITION -- (re: pldg. ( #1 in MDL No. 3103) ) Filed by Defendants/Counter Claimants BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Attachments: #1 Exhibit Exhibit 1 - Disclaimer, #2 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Mazzochi, Deanne) Modified on 2/6/2024 (LH). REMOVED DUPLICATE PARTIES
February 2, 2024 Filing 10 RESPONSE IN OPPOSITION (JOINT) -- (re: pldg. ( #1 in MDL No. 3103) ) Filed by Defendants Formycon AG, #et al.Samsung Bioepis Co., Ltd., Celltrion, Inc. #[Suppress List] (Attachments: #1 Exhibit 1 - SB Motion to Dismiss, #2 Exhibit 2 - RGN Request re CD Cal PI Sched, #3 Exhibit 3 - CD Cal Order re PI Sched, #4 Exhibit 4 - All Asserted Patents, #5 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Traupman, Matthew) Modified on 2/6/2024 (LH). REMOVED DUPLICATE PARTY Modified on 2/7/2024 (LH). EDITED EVENT NAME
January 26, 2024 Filing 9 CORPORATE DISCLOSURE STATEMENT re: pldg. ( #1 in MDL No. 3103) -- Identifying Corporate Parent Samsung Biologics Co., Ltd, Non-Party/Financial Interest Samsung Electronics Co., Ltd., Non-Party/Financial Interest Samsung C&T Corporation for Samsung Bioepis Co., Ltd.. (Attachments: #1 Exhibit A - Corporate Entities, #2 Proof of Service) Associated Cases: MDL No. 3103, WVN/1:23-cv-00094, WVN/1:23-cv-00106 (Traupman, Matthew) Modified on 1/30/2024 (LH). REMOVED DUPLICATE PARTY
January 26, 2024 Filing 8 NOTICE OF APPEARANCE re: pldg.( #1 in MDL No. 3103), Filed by Matthew A Traupman on behalf of Defendant Samsung Bioepis Co., Ltd., (Attachments: #1 Exhibit A - Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3103, WVN/1:23-cv-00094, WVN/1:23-cv-00106 (Traupman, Matthew) Modified on 1/30/2024 (LH). REMOVED DUPLICATE PARTY
January 26, 2024 Filing 7 ORAL ARGUMENT STATEMENT re: pldg. ( #1 in MDL No. 3103) Filed by Plaintiff Regeneron Pharmaceuticals, Inc. (Attachments: #1 Exhibit A Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Berl, David) Modified on 1/31/2024 (LH). REMOVED DUPLICATE PARTIES AND DUPLICATE ATTACHMENT NAMES
January 26, 2024 Filing 6 CORPORATE DISCLOSURE STATEMENT re: pldg. ( #1 in MDL No. 3103) -- Identifying Corporate Parent No Parent Corp. for Regeneron Pharmaceuticals, Inc. (Attachments: #1 Exhibit A Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Berl, David) Modified on 1/30/2024 (LH). REMOVED DUPLICATE PARTIES AND ATTACHMENT NAMES
January 26, 2024 Filing 5 NOTICE OF APPEARANCE re: pldg.( #1 in MDL No. 3103) Filed by David Isaac Berl on behalf of Plaintiff Regeneron Pharmaceuticals, Inc. (Attachments: #1 Exhibit A Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Berl, David) Modified on 1/30/2024 (LH). REMOVED DUPLICATE PARTIES AND ATTACHMENT NAMES
January 12, 2024 Filing 4 ***TEXT ONLY ENTRY***MINUTE ORDER (re: pldg. ( 3 in MDL No. 3103) ) Plaintiff has moved to expedite consideration of its motion to transfer. The Panel considers all motions in due course and is not persuaded to depart from its long-standing practice. The motion for expedited consideration is DENIED. This matter will be set for the March 28, 2024 Hearing Session Order. Signed by Clerk of the Panel Tiffaney D. Pete on 1/12/2024. Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (DLD) Modified on 1/12/2024 (DLD).
January 12, 2024 Filing 3 ***TEXT ONLY NOTICE***NOTICE OF FILING AND PUBLICATION OF BRIEFING SCHEDULE re: pldg. ( #1 in MDL No. 3103) BRIEFING SCHEDULE IS SET AS FOLLOWS:< br< Notices of Appearance due on or before 1/26/2024. Corporate Disclosure Statements due on or before 1/26/2024. Responses due on or before 2/2/2024. Reply, if any, due on or before 2/9/2024. In their briefs, the parties should address what steps they have taken to pursue alternatives to centralization (including, but not limited to, engaging in informal coordination of discovery and scheduling, and seeking Section 1404 transfer of one or more of the subject cases). #Appearance forms (JPML form 18) and #Corporate Disclosure forms can be downloaded from our website. Important: A Corporate Disclosure Form, if required, must be filed, even if one has previously been filed in this MDL.Please visit the #CM/ECF Filing Guidelines < Forms page of our website for additional information.Attorneys must be registered to file in the JPML. Please visit our website for #Registration Information.Signed by Clerk of the Panel Tiffaney D. Pete on 1/12/2024. Associated Cases: MDL No. 3103, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (DLD)
January 12, 2024 Filing 2 MDL Number 3103 Assigned -- MOTION FOR TRANSFER ACCEPTED FOR FILING re: pldg. ( #1 in Pending No. 5) Associated Cases: Pending No. 5, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv -00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (DLD)
January 11, 2024 Filing 1 MOTION TO EXPEDITE (re: pldg. #1 in MDL No. 3103) Filed by David Isaac Berl on behalf of Plaintiff Regeneron Pharmaceuticals, Inc. (Attachments: #1 Proof of Service) Associated Cases: Pending No. 5, CAC/2:24-cv-00264, WVN/1:22-cv-00061, WVN/1:23-cv-00089, WVN/1:23-cv-00094, WVN/1:23-cv-00097, WVN/1:23-cv-00106 (Berl, David) Modified on 1/12/2024 (DLD). REMOVED DUPLICATE PARTIES Modified on 1/16/2024 (DLD). REMOVED DUPLICATE ATTACHMENT NAME AND ADDED MDL LINK.

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Judicial Panel on Multidistrict Litigation's Electronic Court Filings (ECF) System

Search for this case: Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd.
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Regeneron Pharmaceuticals, Inc.
Represented By: Evan T. Leo
Represented By: Jacob E. Hartman
Represented By: Mary Charlotte Y. Carroll
Represented By: Sven Eric Henningson, III
Represented By: David Isaac Berl
Represented By: Adam Pan
Represented By: Andrew E. Goldsmith
Represented By: Andrew V. Trask
Represented By: Anish R Desai
Represented By: Arthur J. Argall, III
Represented By: Christopher M. Pepe
Represented By: David R. Pogue
Represented By: Elizabeth Stotland Weiswasser
Represented By: Ellen E. Oberwetter
Represented By: Haylee Bernal Anderson
Represented By: Jennalee Beazley
Represented By: Jennifer Melien Brooks Crozier
Represented By: Kathryn Schleckser Kayali
Represented By: Kathryn Leicht
Represented By: Kellie C. Van Beck
Represented By: Matthew D. Sieger
Represented By: Natalie C. Kennedy
Represented By: Priyata Y. Patel
Represented By: Raymond S Franks, II
Represented By: Rebecca A. Carter
Represented By: Renee M. Griffin
Represented By: Rhochelle Krawetz
Represented By: Rocco Recce
Represented By: Shaun P. Mahaffy
Represented By: Steven Robert Ruby
Represented By: Teagan J. Gregory
Represented By: Thomas S. Fletcher
Represented By: Tom Yu
Represented By: Yi Zhang
Represented By: Zhen Lin
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Samsung Bioepis Co., Ltd.
Represented By: Chad L Taylor
Represented By: Frank E. Simmerman, Jr.
Represented By: Frank Edward Simmerman, III
Represented By: Laura L. Fairneny
Represented By: Matthew D. Robson
Represented By: Matthew A Traupman
Represented By: Raymond N. Nimrod
Represented By: Sandra K. Law
Represented By: Zachariah B. Summers
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?